miR-10b-5p promotes tumor growth by regulating cell metabolism in liver cancer via targeting SLC38A2

References

• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73(Suppl 1):4–15. doi:10.1002/hep.31288.
   PubMed Web of Science ®Google Scholar
• Chan LK, Tsui YM, Ho DW, Ng IO. Cellular heterogeneity and plasticity in liver cancer. Semin Cancer Biol. 2022. 82:134–49. doi:10.1016/j.semcancer.2021.02.015.
   PubMed Web of Science ®Google Scholar
• Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314. doi:10.1016/j.bbcan.2019.188314.
   PubMed Web of Science ®Google Scholar
• Riddiough GE, Jalal Q, Perini MV, Majeed AW. Liver regeneration and liver metastasis. Semin Cancer Biol. 2021. 71:86–97. doi:10.1016/j.semcancer.2020.05.012.
   PubMed Web of Science ®Google Scholar
• Bao MH, Hypoxia WC. Metabolic reprogramming, and drug resistance in liver cancer. Cells. 2021;10(7):1715. doi:10.3390/cells10071715.
   PubMed Web of Science ®Google Scholar
• Su GL, Altayar O, O’Shea R, Shah R, Estfan B, Wenzell C, Sultan S, Falck-Ytter Y. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. Gastroenterology. 2022;162(3):920–934. doi:10.1053/j.gastro.2021.12.276.
   PubMed Web of Science ®Google Scholar
• Wang X, He Y, Mackowiak B, Gao B. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 2021;70(4):784–95. doi:10.1136/gutjnl-2020-322526.
   PubMed Web of Science ®Google Scholar
• Mohr R, Ozdirik B, Lambrecht J, Demir M, Eschrich J, Geisler L, Hellberg T, Loosen SH, Luedde T, Tacke F, et al. From liver cirrhosis to cancer: the role of micro-RNAs in hepatocarcinogenesis. Int J Mol Sci. 2021;22(3):1492. doi:10.3390/ijms22031492.
   PubMed Web of Science ®Google Scholar
• Yan W, Wu X, Zhou W, Fong MY, Cao M, Liu J, Liu X, Chen C-H, Fadare O, Pizzo DP, et al. Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol. 2018;20(5):597–609. doi:10.1038/s41556-018-0083-6.
   PubMed Web of Science ®Google Scholar
• Yin J, Shi Z, Wei W, Lu C, Wei Y, Yan W, Li R, Zhang J, You Y, Wang X, et al. MiR-181b suppress glioblastoma multiforme growth through inhibition of SP1-mediated glucose metabolism. Cancer Cell Int. 2020;20(1):69. doi:10.1186/s12935-020-1149-7.
   PubMed Web of Science ®Google Scholar
• Liu C, Cai L, Li H. miR185 regulates the growth of osteosarcoma cells via targeting hexokinase 2. Mol Med Rep. 2019. 20:2774–2782. doi:10.3892/mmr.2019.10534.
   PubMed Web of Science ®Google Scholar
• Li W, Li C, Xiong Q, Tian X, Ru Q. MicroRNA-10b-5p downregulation inhibits the invasion of glioma cells via modulating homeobox B3 expression. Exp Ther Med. 2019. 17:4577–4585. doi:10.3892/etm.2019.7506.
   PubMed Web of Science ®Google Scholar
• Yan T, Wang X, Wei G, Li H, Hao L, Liu Y, Yu X, Zhu W, Liu P, Zhu Y, et al. Exosomal miR-10b-5p mediates cell communication of gastric cancer cells and fibroblasts and facilitates cell proliferation. J Cancer. 2021;12(7):2140–50. doi:10.7150/jca.47817.
   PubMed Web of Science ®Google Scholar
• Wang D, Wang Z, Zhang L, Sun S. LncRNA PDCD4-AS1 alleviates triple negative breast cancer by increasing expression of IQGAP2 via miR-10b-5p. Transl Oncol. 2021;14(1):100958. doi:10.1016/j.tranon.2020.100958.
   PubMed Web of Science ®Google Scholar
• Meerson A, Eliraz Y, Yehuda H, Knight B, Crundwell M, Ferguson D, Lee BP, Harries LW. Obesity impacts the regulation of miR-10b and its targets in primary breast tumors. BMC Cancer. 2019;19(1):86. doi:10.1186/s12885-019-5300-6.
   PubMedGoogle Scholar
• Khalighfard S, Alizadeh AM, Irani S, Omranipour R. Plasma miR-21, miR-155, miR-10b, and let-7a as the potential biomarkers for the monitoring of breast cancer patients. Sci Rep. 2018;8(1):17981. doi:10.1038/s41598-018-36321-3.
   PubMedGoogle Scholar
• Wang B, Zhang Y, Zhang H, Lin F, Tan Q, Qin Q, Bao W, Liu Y, Xie J, Zeng Q, et al. Long intergenic non-protein coding RNA 324 prevents breast cancer progression by modulating miR-10b-5p. Aging (Albany NY). 2020;12(8):6680–99. doi:10.18632/aging.103021.
   PubMedGoogle Scholar
• Yang Y, Liu X, Zheng J, Xue Y, Liu L, Ma J, Wang P, Yang C, Wang D, Shao L, et al. Interaction of BACH2 with FUS promotes malignant progression of glioma cells via the TSLNC8–miR-10b-5p–WWC3 pathway. Mol Oncol. 2020;14(11):2936–2959. doi:10.1002/1878-0261.12795.
   PubMed Web of Science ®Google Scholar
• Broer S. Amino acid transporters as targets for cancer therapy: why, where, when, and how. Int J Mol Sci. 2020;21(17):6156. doi:10.3390/ijms21176156.
   PubMed Web of Science ®Google Scholar
• Broer S, Broer A. Amino acid homeostasis and signalling in mammalian cells and organisms. Biochem J. 2017;474(12):1935–63. doi:10.1042/BCJ20160822.
   PubMedGoogle Scholar
• Schioth HB, Roshanbin S, Hagglund MG, Fredriksson R. Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects. Mol Aspects Med. 2013;34(2–3):571–85. doi:10.1016/j.mam.2012.07.012.
   PubMed Web of Science ®Google Scholar
• Morotti M, Bridges E, Valli A, Choudhry H, Sheldon H, Wigfield S, Gray N, Zois CE, Grimm F, Jones D, et al. Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proc Natl Acad Sci U S A. 2019;116(25):12452–61. doi:10.1073/pnas.1818521116.
   PubMed Web of Science ®Google Scholar
• Morotti M, Zois CE, El-Ansari R, Craze ML, Rakha EA, Fan SJ, Valli A, Haider S, Goberdhan DCI, Green AR, et al. Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. Br J Cancer. 2021;124(2):494–505. doi:10.1038/s41416-020-01113-y.
   PubMed Web of Science ®Google Scholar
• Parker SJ, Amendola CR, Hollinshead KER, Yu Q, Yamamoto K, Encarnacion-Rosado J, Rose RE, LaRue MM, Sohn ASW, Biancur DE, et al. Selective Alanine Transporter Utilization Creates a Targetable Metabolic Niche in Pancreatic Cancer. Cancer Discov. 2020;10(7):1018–37. doi:10.1158/2159-8290.CD-19-0959.
   PubMed Web of Science ®Google Scholar
• Nie K, Cai M. SNAT2/SLC38A2 confers the stemness of gastric cancer cells via regulating glutamine level. Dig Dis Sci. 2022;67(7):2948–2956. doi:10.1007/s10620-021-07110-2.
   PubMed Web of Science ®Google Scholar
• Gjymishka A, Palii SS, Shan J, Kilberg MS. Despite increased ATF4 binding at the C/EBP-ATF composite site following activation of the unfolded protein response, system a transporter 2 (SNAT2) transcription activity is repressed in HepG2 cells. J Biol Chem. 2008;283(41):27736–47. doi:10.1074/jbc.M803781200.
   PubMed Web of Science ®Google Scholar
• Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34(3):355–77. doi:10.1016/j.cmet.2022.01.007.
   PubMed Web of Science ®Google Scholar
• Zhang LF, Lou JT, Lu MH, Gao C, Zhao S, Li B, Liang S, Li Y, Li D, Liu M-F, et al. Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma. EMBO J. 2015;34(21):2671–85. doi:10.15252/embj.201591803.
   PubMed Web of Science ®Google Scholar
• Xu Q, Zhang M, Tu J, Pang L, Cai W, Liu X. MicroRNA-122 affects cell aggressiveness and apoptosis by targeting PKM2 in human hepatocellular carcinoma. Oncol Rep. 2015;34(4):2054–64. doi:10.3892/or.2015.4175.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen J, Sun F, Wang Z, Xu W, Yu Y, Ding F, Shen H. miR‑202 functions as a tumor suppressor in hepatocellular carcinoma by targeting HK2. Oncol Lett. 2020. 19:2265–2271. doi:10.3892/ol.2020.11334.
   PubMed Web of Science ®Google Scholar
• Zhang H, Feng Z, Huang R, Xia Z, Xiang G, Zhang J. MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1. Int J Oncol. 2014;45(5):2143–52. doi:10.3892/ijo.2014.2596.
   PubMed Web of Science ®Google Scholar
• Yang H, Cho ME, Li TW, Peng H, Ko KS, Mato JM, Lu SC. MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Invest. 2013;123(1):285–298. doi:10.1172/JCI63861.
   PubMed Web of Science ®Google Scholar
• Kandasamy P, Zlobec I, Nydegger DT, Pujol-Giménez J, Bhardwaj R, Shirasawa S, Tsunoda T, Hediger MA. Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1. Mol Oncol. 2021;15(10):2782–2800. doi:10.1002/1878-0261.12999.
   PubMed Web of Science ®Google Scholar
• Menchini RJ, Chaudhry FA. Multifaceted regulation of the system a transporter Slc38a2 suggests nanoscale regulation of amino acid metabolism and cellular signaling. Neuropharmacology. 2019. 161:107789. doi:10.1016/j.neuropharm.2019.107789.
   PubMed Web of Science ®Google Scholar
• Alvarez ML. Faster experimental validation of microRNA targets using cold fusion cloning and a dual firefly-renilla luciferase reporter assay. Methods Mol Biol. 2014;1182:227–243.
   PubMedGoogle Scholar
• Li H, Wang N, Xu Y, Chang X, Ke J, Yin J. Upregulating microRNA-373-3p promotes apoptosis and inhibits metastasis of hepatocellular carcinoma cells. Bioengineered. 2022;13(1):1304–19. doi:10.1080/21655979.2021.2014616.
   PubMed Web of Science ®Google Scholar